Courses

The Role of PCSK9 Inhibitors in Reducing CV Risk: Patient Selection Criteria and Treatment Initiation Tactics

The Role of PCSK9 Inhibitors in Reducing CV Risk: Patient Selection Criteria and Treatment Initiation Tactics

In this module of a Four-Part Expert Interview Series, Dr. Robert P. Giugliano, along with Dr Christopher P. Cannon, course chair, will examine the role of PCSK9 inhibitors in reducing CV risk. Dr. Guigliano will review optimal patient selection criteria and how it can be applied in daily practice. This module will allow learners to understand the relationship between LDL-C ...
View Course
Further Insights in Lowering LDL Cholesterol: Managing Atherosclerotic Disease in High-Risk Patients

Further Insights in Lowering LDL Cholesterol: Managing Atherosclerotic Disease in High-Risk Patients

In this module of a Four-Part Expert Interview Series, Dr. Marc P. Bonaca, along with Dr. Christopher P. Cannon, course chair, will discuss options for lowering LDL cholesterol in dyslipidemia patients. This will include recent outcomes from clinical trials and the diagnostic criteria of peripheral artery disease. Enabling physicians to recognize physical indicators of PAD will maximize treatment efforts in ...
View Course
Scientific Updates in the Reversal of Direct Oral Anticoagulants for Patients with an Acute Major Bleed

Scientific Updates in the Reversal of Direct Oral Anticoagulants for Patients with an Acute Major Bleed

This continuing education activity will review optimal treatment strategies and recent clinical trial data for patients who require emergent reversal of their direct oral anticoagulant therapy as presented at the American College of Cardiology 2018 in Orlando, Florida. Three expert faculty will analyze clinical profiles of reversal agents and current strategies to treat direct oral anticoagulant associated bleeds in emergent ...
View Course
Advancements in the Prevention and Management of Stroke

Advancements in the Prevention and Management of Stroke

This CME/CNE webcast will highlight recent advancements in the prevention and management of stroke. The expert faculty will discuss best practices for assessing risk as well as the modifiable risk factors of stroke. Recent clinical trial data, including that of combination therapy, will be analyzed, as well as strategies for managing the comorbidities that commonly accompany stroke. Best practices for ...
View Course
The New Era of Preventive Cardiology: Applying PCSK9 Inhibitor Therapeutics to Prevent Heart Attack and Stroke

The New Era of Preventive Cardiology: Applying PCSK9 Inhibitor Therapeutics to Prevent Heart Attack and Stroke

This CME/CNE program is derived from content presented at the National Lipid Association 2018 Scientific Sessions in Las Vegas, Nevada. The five expert faculty, led by Dr. Alan S. Brown, will review best practices for assessing the risk of cardiovascular disease (CVD). Recently released data, including the results of the ODYSSEY and FOURIER trials, will be outlined followed by a ...
View Course
Navigating the Role of PCSK9 Inhibitors in the Prevention of Cardiovascular Events

Navigating the Role of PCSK9 Inhibitors in the Prevention of Cardiovascular Events

This CME activity will review optimal treatment strategies and recent clinical trial data for patients with dyslipidemia, as presented at the American College of Cardiology 2018 in Orlando, Florida. Four expert faculty, led by Dr. Christopher Cannon, will analyze the science of LDL cholesterol and how it relates to cardiovascular events. Recent clinical trial data for PCSK9 inhibitors, including data ...
View Course
PCSK9 Inhibitor Therapeutics 2018: Analyses of Specific Patient Populations Data

PCSK9 Inhibitor Therapeutics 2018: Analyses of Specific Patient Populations Data

This educational program will explore and analyze data for PCSK9 inhibitor therapeutics in specific patient populations. Expert faculty will relay updates regarding recent PCSK9 inhibitor data and dive into how to optimally apply these therapies into clinical practice. Recent dyslipidemia guidelines will also be reviewed. The panel will discuss how to best improve outcomes for dyslipidemia patients, including those with stroke or at ...
View Course
The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options

The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options

The content for this activity is derived from a live symposium titled, “The Important Role of Lipoprotein(a) in Cardiovascular Disease: Present and Future Therapeutic Options” presented at the American Heart Association Scientific Sessions 2017 in Anaheim, California. This CME activity will focus on the role of lipoprotein(a) and its therapeutic options for patients with cardiovascular disease. A review of the ...
View Course
Loading...